OBIO Orchestra BioMed Holdings, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1814114 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,007.4%
TTM net income YoY24.2%
TTM EPS YoY58.3%
Revenue 3-yr CAGR105.4%
Net income 3-yr CAGR—
Margins
Gross margin99.6%
Operating margin-195.4%
Net margin-182.5%
FCF margin-205.7%
EBITDA margin-194.2%
Returns
ROE-221.1%
ROA-53.6%
ROIC (approx.)—
Asset turnover0.29x
Leverage & solvency
Liabilities / assets82.6%
Debt / equity0.00x
Current ratio7.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio6.0%
Payout ratio—
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $33.48M | $2.64M |
| Cost of revenue | $190,000 | $204,000 |
| Gross profit | $33.29M | $2.43M |
| R&D expense | $58.19M | $42.80M |
| SG&A expense | $26.91M | $23.93M |
| Operating income | -$51.81M | -$64.30M |
| Interest expense | — | $297,000 |
| Income tax | $0 | — |
| Net income | -$52.70M | -$61.02M |
| EBITDA | -$51.48M | -$63.99M |
| EPS (basic) | -1.11 | -1.66 |
| EPS (diluted) | -1.11 | -1.66 |
| Weighted avg. shares (diluted) | 47.75M | 36.82M |
| Balance sheet | ||
| Cash & equivalents | $34.69M | $22.26M |
| Short-term investments | $71.82M | $44.55M |
| Receivables | $95,000 | $92,000 |
| Inventory | $310,000 | $173,000 |
| Current assets | $107.91M | $69.17M |
| PP&E, net | $1.72M | $1.38M |
| Total assets | $114.86M | $76.17M |
| Current liabilities | $16.74M | $16.21M |
| Long-term debt | $15.00M | $15.00M |
| Total debt | $15.00M | $15.00M |
| Total liabilities | $51.48M | $43.22M |
| Shareholders' equity | $53.57M | $32.96M |
| Net debt | -$19.69M | -$7.26M |
| Shares outstanding | 57.03M | 38.19M |
| Cash flow statement | ||
| Operating cash flow | -$48.96M | -$50.56M |
| Capital expenditure | $489,000 | $289,000 |
| Free cash flow | -$49.45M | -$50.85M |
| Investing cash flow | -$26.94M | $13.09M |
| Financing cash flow | $88.33M | $29.17M |
| Depreciation & amortization | $327,000 | $308,000 |
| Stock-based compensation | $11.98M | $10.62M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.